广东省肺癌研究所所长

永乐高ylg官网肿瘤医院副院长

香港中文大学（深圳）、华南理工大学医学院、南方医科大学博士生导师；广东省杰出青年医学人才

中国临床肿瘤学会理事，青委副主委，肺癌专业组组长；中华医学会肿瘤早诊早治学组副组长；中国研究型医院学会胸外科专委会青年委员会副主委；广东省医学会肺部肿瘤学分会副主任委员；国际肺癌联盟IASLC官方杂志(J Thorac Oncol，IF 15.6) 副主编。

研究方向：

主要方向为以肺癌外科为主单病种多学科综合治疗，包括IIIA期N2纵隔淋巴结转移肺癌、肺部孤立结节/肺腺癌/GGO分类诊断和处理、胸腔镜微创肺癌根治术、肺癌病理分类和临床实践、人工智能影像-液体活检肺癌早筛分诊系统等。

钟文昭教授团队专注于肺癌多学科综合治疗和外科创新技术探索，依托永乐高ylg官网和广东省肺癌研究所平台，围绕肺癌复发和转移率高的重大难题，建立人工智能影像-液体早筛分诊系统和肺癌围术期精准治疗模式。主持四项国家自然科学基金。以第一作者或通讯作者发表SCI论文54篇，在肿瘤学高影响力杂志，包括Lancet oncol（IF=41.316），J Clin Oncol（IF=44.544）(3篇)，J Thorac Oncol(IF=15.609)（7篇），J Extracell Vesicles(IF=25.841)，Nature Communications（14.919）等，和国际胸心外科四大期刊：JTCVS、ATS、EJCTS、IVCTS发表原创性成果。钟文昭教授参与制定《中国临床肿瘤学会原发性肺癌诊疗指南》，共同主编《肺腺癌病理新分类和临床实践》，参编《胸心外科学》研究生卫生部规划教材，受邀担任世界肺癌大会外科专场主席，担任国际肺癌联盟（IASLC）官方杂志胸部肿瘤学杂志（J Thorac Oncol,IF 15.6）副主编。团队联合国内多家中心，优化卷积神经网络算法，研发人工智能识别系统，提高早期肺癌诊断率；建立基于三维重建-荧光成像流域分析术前规划系统和肺腺癌病理侵袭性模型，优化肺癌手术策略，推动建立“广东省肺癌诊疗一体化联盟”。针对区域淋巴结转移Ⅲ期肺癌治疗难度和争议大，预后不良特点，结合本中心前期临床科研成果，在国内牵头启动Ⅲ期肺癌多学科联合门诊，为来自全国各地的复杂疑难肺癌患者提供从诊断、治疗到随访一站式的个性化服务和多学科诊疗方案，改善患者预后和生活质量，推动科研成果转化落地临床实践。以第一完成人获得2020年广东省科学技术进步奖一等奖，获第十六届丁颖科技奖。

代表性科研成果：

(1) Wenzhao Zhong#, Qun Wang, Weimin Mao, Songtao Xu, Lin Wu, Yucheng Wei, Yongyu Liu, Chun Chen, Ying Cheng, Rong Yin, Fan Yang, Shengxiang Ren, Xiaofei Li, Jian Li, Cheng Huang, Zhidong Liu, Shun Xu, Keneng Chen, Shidong Xu, Lunxu Liu, Ping Yu, Buhai Wang, Haitao Ma, Jinji Yang, Honghong Yan, Xuening Yang, Siyang Liu, Qing Zhou, Yilong Wu; Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial; Journal of Clinical Oncology; 2020; 39(7):713-722 (IF=44.544);

(2) Wenzhao Zhong#, Keneng Chen, Chun Chen, Chundong Gu, Jun Wang, XueNing Yang, Weimin Mao, Qun Wang, Guibin Qiao, Ying Cheng, Lin Xu, Changli Wang, Mingwei Chen, Xiaozheng Kang, Wanpu Yan, Honghong Yan, Riqiang Liao, Jinji Yang, Xuchao Zhang, Qing Zhou, Yilong Wu; Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 EGFR-Mutant Non-Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study; Journal of Clinical Oncology; 2019; 37(25): 2235-2245 (IF=44.544);

(3) Wenzhao Zhong#, Qun Wang, Weimin Mao, Songtao Xu, Wu Lin, Yi Shen, Yongyu Liu, Chun Chen, Ying Cheng, Lin Xu, Jun Wang, Ke Fei, Xiaofei Li, Jian Li, Cheng Huang, Zhidong Liu, Shun Xu, Keneng Chen, Shidong Xu, Lunxu Liu, Ping Yu, Buhai Wang, Haitao Ma, Honghong Yan, Xuening Yang, Qing Zhou, Yilong Wu; Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study; The Lancet Oncology;  2018; 19(1): 139-148 (IF=41.316);

(4) Siyang Liu#, Hua Bao, Qun Wang, Weimin Mao, Yedan Chen, Xiaoling Tong, Songtao Xu, Lin Wu, Yucheng Wei, Yongyu Liu, Chun Chen, Ying Cheng, Rong Yin, Fan Yang, Shengxiang Ren, Xiaofei Li, Jian Li, Cheng Huang, Zhidong Liu, Shun Xu, Keneng Chen Shidong Xu , Lunxu Liu, Ping Yu, Buhai Wang, Haitao Ma, Honghong Yan, Song Dong, Xuchao Zhang, Jian Su, Jinji Yang, Xuening Yang, Qing Zhou, Xue Wu, Yang Shao, Wenzhao Zhong*, Yilong Wu*; Genomic signatures define three subtypes of EGFRmutant stage II–IIInonsmallcell lung cancer with distinct adjuvant therapy outcomes; Nature Communications; 2021; 12(1):6450 (IF=14.919);

(5) Jiatao Zhang, Hao Qin, Fiona Ka Man Cheung, Jian Su, Dadong Zhang, Shiyi Liu, Lixiao Fang, Jing Qin, Juntao Lin, Benyuan Jiang, Song Dong, Riqiang Liao, Qiang Nie, Xuening Yang, Haiyan Tu, Qing Zhou, Jinji Yang, Xuchao Zhang, Yanan Zhang, Yilong Wu*, Wenzhao Zhong*; Plasma extracellular vesicle microRNAs for pulmonary ground-glass nodules; Journal of Extracellular Vesicles; 2019; 8(1): 1663666, 1-13 (IF=25.841);

(6) Chao Zhang, Jianjun Zhang, Fangping Xu, Yinguang Wang, Zhi Xie, Jian Su, Song Dong, Qiang Nie, Yang Shao, Qing Zhou, Jinji Yang, Xuening Yang, Xuchao Zhang, Zhi Li, Yilong Wu, Wenzhao Zhong*; Genomic Landscape and Immune Microenvironment Features of Preinvasive and Early Invasive Lung Adenocarcinoma; Journal of Thoracic Oncology; 2019; 14(11):1912-1923 (IF=15.609);

(7) Chao Zhang#, Shao-lei Li#, Qiang Nie, Song Dong, Yang Shao, Xue-ning Yang, Yi-long Wu, Yue Yang, Wen-zhao Zhong*; Neoadjuvant Crizotinib in Resectable Locally Advanced Non–Small Cell Lung Cancer with ALK Rearrangement; Journal of Thoracic Oncology; 2019; 14(4):726-731 (IF=15.609);

(8) Wenfang Tang#, Min Wu, Hua Bao, Yang Xu, Jieshan Lin, Yi Liang, Yu Zhang, Xiangpeng Chu, Zhenbin Qiu, Jian Su, Jiatao Zhang, Chao Zhang, Fangping Xu, Jinghua Chen, Rui Fu, Ying Chen, Tao Yang, Qingke Chen, Tingting Wu, Xue Wu, Yang Shao 1, Jiantao Zheng 1, Zhi Xie, Zhiyi Lv, Song Dong, Yilong Wu, Wenzhao Zhong*; Timing and origins of local and distant metastases in lung cancer; Journal of Thoracic Oncology; 2021; 16(7):11361148 (IF=15.609);

(9) Chao Zhang#, Kai Yin#, Si-Yang Liu#, Li-Xu Yan, Jian Su, Yi-Long Wu, Xu-Chao Zhang, Wen-Zhao Zhong*, Xue-Ning Yang*; Multiomics analysis reveals a distinct response mechanism in multiple primary lung adenocarcinoma after neoadjuvant immunotherapy; Journal for Immunotherapy of Cancer; 2021; 9:e002312  (IF=13.754);

(10) Zhen-Bin Qiu#, Chao Zhang, Xiang-Peng Chu, Fei-Yue Cai, Xue-Ning Yang, Yi-Long Wu, Wen-Zhao Zhong*; Quantifying invasiveness of clinical stage IA lung adenocarcinoma with computed tomography texture features; Journal of Thoracic and Cardiovascular Surgery; 2021; S0022-5223(20)33447-4 (IF=5.209).